Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/apt.13331 http://scihub22266oqcxt.onion/10.1111/apt.13331 C5014135!5014135!26201312     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 278.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Aliment+Pharmacol+Ther 2015 ; 42 (6): 685-95 Nephropedia Template TP {{tp|p=26201312|t=2015. Randomised clinical trial: a dose?ranging study of vonoprazan, a novel potassium?competitive acid blocker, vs lansoprazole for the treatment of erosive oesophagitis |pdf=|usr=}}{{26201312}} gab.com Text Randomised clinical trial: a dose ranging study of vonoprazan, a novel potassium competitive acid blocker, vs lansoprazole for the treatment of erosive oesophagitis JO: Aliment Pharmacol Ther http://www.kidney.de/pget.php?&tw=1&pmid=26201312 #FOAvip Background: The potassium?competitive acid blocker vonoprazan (VPZ) has potent acid?inhibitory effects and may offer clinical advantages over conventional therapy for acid?related disorders. Aim: To investigate the efficacy and safety of VPZ in patients with erosive oesophagitis (EO). Methods: In this multicentre, randomised, double?blind, parallel?group, dose?ranging study, patients ?20 years with endoscopically confirmed EO [Los Angeles (LA) grades A?D] received VPZ 5, 10, 20 or 40 mg, or lansoprazole (LPZ) 30 mg once daily for 8 weeks. The primary endpoint was the proportion of healed EO subjects as shown by endoscopy at week 4. Results: A total of 732 subjects received VPZ or LPZ. The proportion of healed EO subjects at week 4 was 92.3%, 92.5%, 94.4%, 97.0% and 93.2%, respectively, with VPZ 5, 10, 20 and 40 mg and LPZ 30 mg. All VPZ doses were non?inferior to LPZ when adjusted for baseline LA grades A/B and C/D. Among those with LA grades C/D, the proportions of healed EO subjects were 87.3%, 86.4%, 100%, 96.0% and 87.0%, respectively, with VPZ 5, 10, 20 and 40 mg and LPZ 30 mg. The incidence of adverse events was similar across the groups. Conclusions: Vonoprazan was effective and non?inferior to LPZ in healing EO. VPZ 20 mg or higher was highly efficacious for severe EO (LA grades C/D). VPZ was associated with no safety concern during this 8?week study, while there was a dose?dependent increase in serum gastrin. Once?daily VPZ 20 mg is the recommended clinical dose for treating EO. Twit Text FOAVip Randomised clinical trial: a dose ranging study of vonoprazan, a novel potassium competitive acid blocker, vs lansoprazole for the treatment of erosive oesophagitis ????Aliment Pharmacol Ther http://www.kidney.de/pget.php?&tw=1&pmid=26201312 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26201312 #FOAvip English Wikipedia <ref>{{Cite pmid|26201312}}</ref> Randomised clinical trial: a dose?ranging study of vonoprazan, a novel potassium?competitive acid blocker, vs lansoprazole for the treatment of erosive oesophagitis #MMPMID26201312 Ashida K; Sakurai Y; Nishimura A; Kudou K; Hiramatsu N; Umegaki E; Iwakiri K; Chiba T Aliment Pharmacol Ther 2015[Sep]; 42 (6): 685-95 PMID26201312show ga Background: The potassium?competitive acid blocker vonoprazan (VPZ) has potent acid?inhibitory effects and may offer clinical advantages over conventional therapy for acid?related disorders. Aim: To investigate the efficacy and safety of VPZ in patients with erosive oesophagitis (EO). Methods: In this multicentre, randomised, double?blind, parallel?group, dose?ranging study, patients ?20 years with endoscopically confirmed EO [Los Angeles (LA) grades A?D] received VPZ 5, 10, 20 or 40 mg, or lansoprazole (LPZ) 30 mg once daily for 8 weeks. The primary endpoint was the proportion of healed EO subjects as shown by endoscopy at week 4. Results: A total of 732 subjects received VPZ or LPZ. The proportion of healed EO subjects at week 4 was 92.3%, 92.5%, 94.4%, 97.0% and 93.2%, respectively, with VPZ 5, 10, 20 and 40 mg and LPZ 30 mg. All VPZ doses were non?inferior to LPZ when adjusted for baseline LA grades A/B and C/D. Among those with LA grades C/D, the proportions of healed EO subjects were 87.3%, 86.4%, 100%, 96.0% and 87.0%, respectively, with VPZ 5, 10, 20 and 40 mg and LPZ 30 mg. The incidence of adverse events was similar across the groups. Conclusions: Vonoprazan was effective and non?inferior to LPZ in healing EO. VPZ 20 mg or higher was highly efficacious for severe EO (LA grades C/D). VPZ was associated with no safety concern during this 8?week study, while there was a dose?dependent increase in serum gastrin. Once?daily VPZ 20 mg is the recommended clinical dose for treating EO. äRandomised clinical trial: a dose?ranging study of vonoprazan, a novel(epmc).pdf DeepDyve Pubget Overpricing